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Purpose: To investigate the safety and effectiveness of a novel thrombolytic, alfimeprase, in catheter-directed thrombolysis
(CDT) of acute peripheral arterial occlusions (PAO).
Methods: Between April 2005 and March 2007, patients with acute PAO (Rutherford class I or IIa) of a lower extremity
and onset of symptoms within 14 days prior to randomization were included. Studies HA004 and HA007 enrolled
respectively 300 and 102 patients. Both studies HA004 and HA007 were placebo-controlled. HA004 had two placebo
arms, intrathrombus and perithrombus, while HA007 had intrathrombus placebo arm. HA004 was partially double-
blind (perithrombus group was not blinded) and HA007 was double-blind. Patients were randomized to intrathrombus
alfimeprase (0.3 mg/kg), intrathrombus (IT) placebo, or perithrombus (PT) placebo (HA004 only) in two divided
weight-based infusions 2 hours apart. Depending on arteriographic results after treatment, patients received no further
intervention or underwent endovascular therapy or open vascular surgery. The primary endpoint of both studies was
efficacy of alfimeprase compared with placebo as measured by avoidance of an open vascular surgery procedure at 30 days.
Results:The avoidance of open vascular surgery at 30 days was seen in 52 (34.9%), 42 (37.2%), and 7 patients (18.4%) with
alfimeprase, IT placebo, and PT placebo in HA004 and 15 (29.4%) and 9 patients (17.6%) with alfimeprase and IT
placebo in HA007; differences between alfimeprase and IT placebo were not statistically significant. Results were similar
for secondary endpoints, including arterial flow restoration in 4 hours, 30-day ankle-brachial index, index limb pain
severity, and hospital stay duration. The overall rate of adverse events was higher with alfimeprase than placebo.
Hemorrhagic and peripheral embolic event rates with alfimeprase were 23% (34 patients) and 10.1% (15 patients) in
HA004 and 9.4% (5 patients) and 9.8% (5 patients) in HA007; rates with IT placebo were 11% (12 patients, P  .107)
and 5% (5 patients, P  .148) in HA004 and 10% (5 patients, P  .982) and 0% in HA007 (P  .07). No deaths were
related to study drug administration.
Conclusions:CDT for acute PAOwith alfimeprase was as safe as placebo. However, alfimeprase was nomore effective than
placebo in increasing 30-day surgery-free survival. The surprising effectiveness of placebo alone demonstrates that the
inclusion of a placebo arm is essential to the design of future lytic trials. ( J Vasc Surg 2010;51:600-9.)Current treatment options for acute peripheral arterial
and graft occlusion (PAO) include open surgical therapy
and endovascular treatments, often involving catheter-
directed thrombolysis. In addition to restoring arterial flow
by dissolving an occluding thombus, thrombolysis can
unmask the underlying lesion, which can be treated with a
less invasive percutaneous procedure and potentially con-
vert an emergent intervention to an elective procedure with
less risk to the patient. Several randomized controlled trials
comparing safety and efficacy of thrombolytic therapy to
surgery as the initial therapy in patients with acute lower
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600extremity arterial and graft occlusions have confirmed these
theoretic advantages. The Surgery vs Thrombolysis for
Ischemia of the Lower Extremity (STILE) trial showed that
in patients with acute (symptoms less than 14 days) lower
extremity ischemia, catheter-directed thrombolysis with
recombinant tissue plasminogen activator (rt-PA) or uroki-
nase (UK) was associated with improved amputation-free
survival and shorter hospital stays in comparison to sur-
gery.1,2 The Thrombolysis or Peripheral Arterial Surgery
(TOPAS) trial showed equivalent 1-year amputation-free
survival rates in the UK-mediated thrombolysis group and
surgery group, but both studies showed that the need for
and magnitude of open surgery were significantly reduced
with the thrombolysis group.1,3
Conventional thrombolytic agents act indirectly to
cause dissolution of fibrin by activation of plasminogen.
This indirect mechanism results in a relatively slow onset of
action. The average time to achieve lysis ranges from 24 to
36 hours in acute limb ischemia.4 Critics of thrombolysis
point out that this slow onset of action may lead to a
prolonged tissue ischemia in the setting of acute arterial
occlusion and greater tissue damage. In addition, circulat-
ing plasmin may dissolve both pathologic and hemostatic
thrombi, predisposing to remote site bleeding. Reported
hemorrhagic complication rates are approximately 5% to
lic blo
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cases.4 Due to these inherent limitations of thrombolytic
therapy, significant interest exists in developing thrombo-
lytic agents such as alfimeprase that act more directly on the
thrombotic process.
Alfimeprase is a recombinant protein of the enzyme
fibrolase, a zinc metalloprotease originally isolated from the
venom of southern copperhead snake. Alfimeprase directly
degrades fibrin alpha chain and has no interaction with
plasminogen. This direct mechanism is evidenced by results
from preclinical studies showing that alfimeprase achieved
thrombolysis up to six times faster than traditional plasmin-
ogen activators.5 The second unique property of alfime-
prase lies in its clearance. In addition to having a short
median half-life of 15 minutes, alfimeprase is immediately
inactivated by alpha-2 macroglobulin (2M) in the sys-
temic circulation, which would theoretically decrease the
risk of remote site bleeding.
The two multicenter, randomized studies presented
here were designed to compare the efficacy and safety of
catheter-administered alfimeprase and placebo as initial
treatment in patients with acute peripheral arterial and graft
occlusion.
METHODS
Patients
Studies HA004 and HA007 were multinational, mul-
ticenter (70 and 43 centers, respectively), randomized,
Table I. Inclusion and exclusion criteria
Inclusion
● Age 18 or older
● Acute PAO of a lower extremity with onset of symptoms within
14 days prior to randomization
● Acute index limb ischemia classified as SVS/ISCVS class I or II
caused by occlusion of a native artery and/or bypass graft (vein
prosthetic)
● Need for surgical intervention in the event of unsuccessful thro
bolysis
● Available for follow-up assessments
DBP,Diastolic blood pressure; PAO, peripheral arterial occlusion; SBP, systo
for Cardiovascular Surgery.partially double-blind (HA004) or double-blind (HA007),placebo-controlled trials. Enrollment was limited to pa-
tients age 18 or older with acute PAO of a lower extremity
and onset of symptoms within 14 days prior to randomiza-
tion who met the inclusion and exclusion criteria shown in
Table I. The studies were approved by Institutional Review
Boards of participating institutions. In each study, a Data
Safety Monitoring Board (DSMB) of two physicians and
one biostatistician otherwise unrelated to the study period-
ically reviewed safety data and made recommendations
about study continuation.
Primary and secondary endpoints
The primary endpoint of both studies was efficacy of
alfimeprase compared with placebo as measured by avoid-
ance of an open vascular surgery procedure at 30 days.
Prospectively defined secondary endpoints are listed in
Table II.
Randomization and treatment
HA004 was partially double-blind and HA007 was
double-blind. In both studies, the patients, investigators,
sponsor, and clinical monitors were blinded to treatment
assignment for patients randomized to receive alfimeprase
or intrathrombus (IT) placebo. The assigned treatment was
not identified on the medication kit or vials. HA004 inves-
tigators were unblinded to treatment assignment for pa-
tients randomized to perithrombus (PT) placebo. Both
Exclusion
● Contraindication to systemic anticoagulation
● History of endovascular procedure or open vascular
surgery on the index limb within the last 30 days
● History of significant acute or chronic kidney disease
that would have precluded contrast angiography
● Known allergy to contrast agents
● History of heparin-induced thrombocytopenia
● Participation in a study of an investigational device or
agent within 30 days prior to randomization
● Any thrombolytic therapy within 30 days (HA004) or 5
days (HA007) prior to randomization
● Past participation in an alfimeprase clinical trial
● Women who were pregnant, lactating, or not using
adequate contraception
● Investigator inability to advance guidewire through
index occlusion
Also in HA004:
● History of hypersensitivity to aspirin
● Uncontrolled hypertension at baseline (SBP  180 mm
Hg, DBP  110 mm Hg)
● Hematocrit  30% (if not actively bleeding could be
entered if transfused to  30%)
● Platelet count  100  109/L
● Medically unable to withstand an open vascular surgical
procedure
od pressure; SVS/ISCVS, Society of Vascular Surgery/International SocietyA
or
m-studies used a standardized acute PAO treatment algorithm
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interspecialty treatment bias.
After written informed consents had been obtained,
patients who met all eligibility criteria (Table I) were taken
to the endovascular suite. Following the initial diagnostic
angiogram and identification of the index thrombotic oc-
clusive arterial lesion, guidewire passage of the index occlu-
sion was attempted. If successful, authorized site staff ob-
tained the blinded treatment assignment via an interactive
voice response system serviced by a third party.
Patients were randomized in HA004 in a 4:3:1 ratio to
receive IT alfimeprase (0.3 mg/kg total dose), IT placebo,
or PT placebo, respectively, and in HA007 in a 1:1 ratio to
receive IT alfimeprase or IT placebo. A side-hole catheter
(AngioDynamics UniFuse Infusion System, 5 cm or 10 cm
at the investigator’s discretion; AngioDynamics, Queens-
bury, NY) was placed within the thrombus for IT adminis-
tration and was positioned intra-arterially, proximal to the
target thrombotic occlusion but not within the thrombus,
for PT placebo administration. All patients received two-
thirds of the dose as the first infusion and one-third as the
second infusion approximately 2 hours later; both infusions
were given as 1 mL/min pulsed boluses. Infusion of the
Table II. Study endpoints
Primary endpoint
● Rate of 30-day open vascular surgery avoidance
Secondary endpoints
● Rate of arterial flow restoration at 4 hours after the initiation
of first dose of study drug, defined as grade 2 or grade 3
thrombolysis as measured by arteriogram in which
3  near-complete or complete thrombolysis with arterial flow
2  incomplete (partial) thrombolysis with arterial flow
1  incomplete (partial) thrombolysis without arterial flow
0  no thrombolysis, no change in the occlusion from
baseline
● Rate of improvement in ABI at 30 days, defined in HA004 as
an increase of  0.15 (magnitude of increase was not specified
in HA007)
● Adverse events, serious adverse events, major bleeding events,
intracranial hemorrhage, peripheral embolic events,
hypotension (HA004), all-cause mortality, surgical and
endovascular procedures, and amputation
Additional Secondary Endpoints in HA004
● Change in index limb pain severity score at 30 days (using
Rutherford pain severity scores from 0  asymptomatic to
4  ischemic rest pain)
● Change in the severity of planned surgical procedures at 30
days (ranked from limb amputation as the most severe to
minor procedures such as digital amputation or fasciotomy)
● Length of hospital stay due to index occlusion up to 30 days
● Rate of patients admitted to the ICU related to the acute
PAO episode or treatment in the first 30 days
● Length of ICU stay for patients entering the ICU in the first
30 days
Additional secondary endpoint in HA007
● Change in Walking Impairment Questionnaire functional
status scores that assessed walking distance, speed, and stair
climbing12
ABI,Ankle-brachial index; ICU, intensive care unit; PAO, peripheral arterial
occlusion.lytic agent (or placebo) was completed at 4 hours. Alfime-prase and placebo were supplied byNuvelo Inc (San Carlos,
Calif) as lyophilized powder (identical except for the active
ingredient) for reconstitution with sterile water for in-
jection and further dilution with a diluent provided by
Nuvelo.
Patients in both studies were clinically monitored and
assessed by a follow-up arteriogram 4 hours after initiation
of the first study drug infusion. Depending on arteriogram
findings, patients received no further intervention or un-
derwent endovascular therapy or open vascular surgery.
Use of other thrombolytic therapy was prohibited through
day 30 follow-up, unless deemed necessary for other med-
ical conditions such as acute myocardial infarction, pulmo-
nary embolus, or stroke. Investigators followed the Acute
PAO Management Algorithm, which was modified from
the recommendations for the Ideal Management Algo-
rithm for the Treatment of Acute Limb Ischemia.6 Patients
were evaluated posttreatment at 18 to 24 hours (or hospital
discharge), day 3 (or hospital discharge), day 7 (or hospital
discharge), and day 30, with follow-up on days 90 and 180,
during which time, vital signs and physical examination
including pulse exam, ABI measurements; hematocrit, he-
moglobin and platelet levels; serum chemistry; and pain
severity score were monitored. On day 30, anti-alfimeprase
antibodies were checked.
Enrollment began in April 2005 for HA004 and April
2006 for HA007. HA004 was completed in March 2007.
Based on the results of HA004 and the unplanned interim
analysis of HA007, the latter study was terminated in
March 2007.
Statistical analysis
The planned sample size for each study across the IT
alfimeprase and IT placebo groups was 300 patients assum-
ing 30-day open vascular surgery avoidance rates of 61% for
alfimeprase, based on the results of prior studyHA002, and
40% for IT placebo, chosen as a conservative estimate to
provide a safety margin since no placebo data were avail-
able. Sample size was estimated using a two-sided two-
group 2 test, 90% power at the 0.05 significance level, and
a 4:3 (HA004) or 1:1 (HA007) ratio of allocation. Ran-
domization for each study was generated by a third party
using a centrally blocked randomization method. No strat-
ification variables were used in either study.7
All statistical tests were two-sided and performed at the
0.05 significance level. The inferential statistical analysis of
efficacy endpoints was conducted between the alfimeprase
and IT placebo regimens. The primary efficacy endpoint
analysis compared the 30-day open vascular surgery avoid-
ance rate between the treatment arms according to Pear-
son’s 2 using the FREQ (frequency cross tabulation)
procedure within SAS (Statistical Analysis System; SAS
Institute, Cary, NC). An odds ratio and 95% confidence
interval (CI) and percentage relative improvement rate
were calculated. Secondary efficacy endpoints were tested
sequentially. Both studies included additional exploratory
outcomes and exploratory subgroup analyses. Based on the
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 3 Han et al 603safety findings of prespecified analyses in HA004, ad hoc
analyses were performed to further evaluate certain events.
An unplanned interim analysis of efficacy and safety and a
futility analysis were performed for HA007.
RESULTS
Demographics and disposition
In HA004, 300 patients were randomized (149 alfime-
prase, 113 IT placebo, 38 PT placebo). The intent-to-treat
(ITT) efficacy analysis used this population. The safety
analysis was performed by treatment group and included
297 patients (148 alfimeprase, 111 IT placebo, 38 PT
placebo) who received treatment; three randomized pa-
tients never received study treatment. In HA007, 102
patients were randomized, 51 to each treatment group, and
all but one patient randomized to placebo received treat-
ment. Patient disposition is shown in Figs 1 and 2.
Demographic and baseline characteristics were similar
across treatment groups (Table III). The index occlusion
was most commonly of a native artery (68%), with an
average length of occlusion of 15 cm (range, 2-120) and an
average duration of acute PAO symptoms of 8 days.
Efficacy
HA004. The difference in rate of 30-day open vascu-
lar surgery avoidance between alfimeprase and IT placebo
Fig 1. Patient disposition in HA004. AE, Adverse
thrombus.was not statistically significant (Table IV). A similar pattern
Fig 2. Patient disposition in study HA007. IT, Intrathrombus;event; IT, intrathrombus; ITT, intent-to-treat; PT, peri-ITT, intent-to-treat.
D, sta
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markedly lower rates with PT placebo, was seen for arterial
flow restoration at 4 hours, 30-day ABI, index limb pain
severity, and severity of planned surgical procedure (Table
IV). For the alfimeprase, IT placebo, and PT placebo
groups, respectively, the median hospital stay was 10, 9,
and 10 days; the proportion of patients admitted to the
intensive care unit (ICU) in the first 30 days was 47.7%
(71/149), 52.2% (59/113), and 65.8% (25/38); and the
median ICU stay was 2 days for each group. Greater efficacy
was observed with alfimeprase in longer clots and with smaller
decreases in 2M (Tables V and VI). The 30-day open vascu-
lar surgery avoidance rate was also evaluated by type of vessel.
Alfimeprase provided no benefit for native arteries, with rates
of 37.4% and 45.7% in the alfimeprase and IT placebo groups,
respectively (P  .180), but suggested a benefit in graft
occlusion, with a rate of 30.0% in the alfimeprase group
compared with 15.6% in the IT placebo group (P .0073).
HA007. The rate of 30-day open vascular surgery
Table III. Demographic and baseline characteristics in bo
Alfimeprase
(N  149)
Sex – male, N 110 (73.8%)
Age, years
Mean (SD) 61.8 (12.41)
Range 21-93
Race, N
Caucasian 136 (91.3%)
African descent 4 (2.7%)
Hispanic 8 (5.4%)
Asian 0 (0.0%)
Other 1 (0.7%)
Diabetes 25 (16.8%)
Hypertension 103 (69.1%)
Hypercholesterolemia or hyperlipidemia 47 (31.5%)
Smoker 96 (64.4%)
Location of clot, N
Femoral 90 (60.4%)
Popliteal 36 (24.2%)
External iliac 11 (7.4%)
Common iliac 10 (6.7%)
Anterior tibial 2 (1.3%)
Posterior tibial 0 (0.0%)
Peroneal 0 (0.0%)
Vessel type, N
Native artery 99 (66.4%)
Prosthetic graft 35 (23.5%)
Vein graft 15 (10.1%)
Occlusion type, N
Thrombotic 130 (87.2%)
Embolic 19 (12.8%)
Occlusion length, cm
Mean (SD) 19.9 (14.66)
Range 3-70
Symptom duration, days
Mean (SD) 7.9 (3.74)
Range 1-21
IT, Intrathrombus; PAO, peripheral arterial occlusion; PT, perithrombus; Savoidance was 29.4% in the alfimeprase group and 17.6% inthe IT placebo group, which was not a statistically signifi-
cant difference (Table IV). The same trend toward the
higher rates of improvement with alfimeprase than IT
placebo was seen for arterial flow restoration at 4 hours and
30-day ABI. Themedian change from baseline at day 30 for
the Walking Impairment Questionnaire was 0 for both
treatment groups for all 3 measures (walking distance,
walking speed, and stair climbing).
To facilitate the DSMB recommending whether to con-
tinue, stop, or modify the study, a futility analysis was per-
formed. The results showed that the conditional power for
success given continuation of the observed response rate
trends were 70.7% and 63.3% for the primary and secondary
arterial flow restoration endpoints, respectively. Although
DSMB did not recommend study discontinuation based on
safety concerns, the sponsor elected to unblind the analysis.
The sponsor concluded that the delivery method used for
alfimeprase was not optimal and terminated the study, with
the authority granted to the sponsor, according to theDSMB
udies (ITT population)
004 HA007
lacebo
113)
PT placebo
(N  38)
Alfimeprase
(N  51)
IT placebo
(N  51)
(69.0%) 30 (78.9%) 41 (80.4%) 40 (78.4%)
(11.73) 64.4 (11.87) 61.1 (11.64) 60.9 (11.41)
-92 30-83 35-83 41-83
(88.5%) 35 (92.1%) 47 (92.2%) 49 (96.1%)
(2.7%) 1 (2.6%) 2 (3.9%) 0 (0.0%)
(8.0%) 2 (5.3%) 0 (0.0%) 0 (0.0%)
(0.0%) 0 (0.0%) 2 (3.9%) 1 (2.0%)
(0.9%) 0 (0.0%) 0 (0.0%) 1 (2.0%)
(22.1%) 11 (28.9%) 9 (17.6%) 6 (11.8%)
(62.8%) 28 (73.7%) 36 (70.6%) 31 (60.8%)
(31.0%) 23 (60.5%) 22 (43.1%) 14 (27.5%)
(71.7%) 27 (71.1%) 37 (72.5%) 34 (66.7%)
(50.4%) 19 (50.0%) 27 (52.9%) 24 (47.1%)
(24.8%) 10 (26.3%) 13 (25.5%) 15 (29.4%)
(8.8%) 6 (15.8%) 3 (5.9%) 5 (9.8%)
(8.0%) 3 (7.9%) 5 (9.8%) 5 (9.8%)
(2.7%) 0 (0.0%) 1 (2.0%) 1 (2.0%)
(3.5%) 0 (0.0%) 1 (2.0%) 1 (2.0%)
(1.8%) 0 (0.0%) 1 (2.0%) 0 (0.0%)
(71.7%) 21 (55.3%) 37 (72.5%) 39 (76.5%)
(17.7%) 14 (36.8%) 11 (21.6%) 11 (21.6%)
(10.6%) 3 (7.9%) 3 (5.9%) 1 (2.0%)
(92.0%) 35 (92.1%) 48 (94.1%) 40 (78.4%)
(8.0%) 3 (7.9%) 3 (5.9%) 11 (21.6%)
(16.44) 20.6 (15.06) 17.8 (12.68) 15.7 (14.21)
-120 3-70 2-50 2-70
(3.82) 7.7 (4.13) 8.3 (3.75) 8.2 (3.45)
-19 1-15 1-14 2-14
ndard deviation.th st
HA
IT p
(N 
78
62.1
37
100
3
9
0
1
25
71
35
81
57
28
10
9
3
4
2
81
20
12
104
9
18.9
2
8.3
1Charters.
the h
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HA004. Adverse events (AEs) were reported for 80%
of patients in the alfimeprase group, 67% in the IT placebo
group (P  .0179), and 71% in the PT placebo group
(Table VII). Fourteen patients died: nine (6%) in the
alfimeprase group, four (4%) in the IT placebo group (P 
.537), and one (3%) in the PT placebo group; no death was
considered related to study drug. In the alfimeprase, IT
Table IV. Efficacy endpoints summary in HA004 (ITT po
Alfimeprase
(N  149)
30-day open vascular surgery free ratec 52 (34.9%)
P  .704
Arterial flow restoration rate 4 hours
after first dose 69 (46.3%)
P  .138
30-day ABI improvement rated 37 (24.8%)
P  .732
Index limb pain severity improvement
rate at 30 days 41 (27.5%)
P  .886
Change in severity of planned surgical
procedure at 30 days
Less severe 61 (40.9%)
No change 42 (28.2%)
More severe 46 (30.9%)
P  .268
ABI, Ankle-brachial index; IT, intrathrombus; ITT, intent-to-treat; PT, per
aThe P value compared alfimeprase with IT placebo.
bFor change in severity of planned surgical procedure, the P value compare
cPearson’s 2 was used for binary outcomes.
dABI was the higher of posterior tibial or dorsalis pedis pressure divided by
Table V. Flow restoration rate at 4 hours and change in a
population)
Occlusion length
Flow restoration ra
Prevalence Alfimeprase IT p
 10 cm 27.9% 59.5% 5
10 to  20 cm 31.3% 33.3% 3
20 to  30 cm 13.7% 41.7% 4
30 to  40 cm 13.4% 52.6% 3
 40 cm 13.0% 45.5% 1
2M, Alpha-2 macroglobulin; CI, confidence interval; IT, intrathrombus.
Table VI. Flow restoration rate at 4 hours by degree of
alpha-2 macroglobulin binding in HA004 (ITT
population)
Alfimeprase IT placebo
No early 2M decline 70% 37%
Rapid 2M decline 45% 37%
2M, Alpha-2 macroglobulin; IT, intrathrombus.placebo, and PT placebo groups, respectively, SAEs werereported for 37%, 29%, (P  .203 IT placebo vs alfime-
prase) and 26% of patients, and SAEs considered related
to study drug were reported for 6%, 3%, and 0% of
patients.
One ischemic stroke occurred in the alfimeprase group,
and no intracranial hemorrhage was observed in HA004.
Hemorrhagic events were seen in 23%, 11%, and 32% of
patients in the alfimeprase, IT placebo, and PT placebo
groups, respectively, and peripheral embolic events in 10%,
5%, and 0% of patients (P  .148 alfimeprase vs IT
placebo).
Based on results of the prespecified analyses, ad hoc
analyses were conducted for hemorrhagic, hypotensive,
peripheral embolic, cardiac, infection events, and mortality
to attempt to identify potential contributing factors.
The risk of hemorrhagic events did not appear to be
affected by baseline or nadir 2M concentration or by
baseline anticoagulant or antiplatelet use. The risk appeared
tion)
004 HA007
lacebo
113)
PT placebo
(N  38)
Alfimeprase
(N  51)
IT placebo
(N  51)
37.2%) 7 (18.4%) 15 (29.4%) 9 (17.6%)
P  .1613
37.2%) 6 (15.8%) 18 (35.3%) 12 (23.5%)
P  .1923
23.0%) 3 (7.9%) 6 (11.8%) 4 (7.8%)
P value not determined
28.3%) 5 (13.2%)
47.8%) 11 (28.9%)
25.7%) 17 (44.7%)
26.5%) 10 (26.3)
bus.
evere against more severe and no change.
ighest brachial pressure.
2 macroglobulin by occlusion length in HA004 (ITT
4 hours Mean change in 2M at 4 h
as a % of baseline in the
alfimeprase groupo Odds ratio (95% CI)
1.21 (0.47-3.09) 31.3%
1.04 (0.41-2.61) 36.3%
1.00 (0.25-4.08) 31.0%
2.44 (0.61-9.80) 37.6%
4.17 (0.74-23.61) 21.0%pula
HA
IT p
(N 
42 (
5a
42 (
1a
26 (
3a
32 (
0a
54 (
29 (
30 (
6a,b
ithrom
s less slpha-
te at
laceb
4.8%
2.5%
1.7%
1.3%
6.7%to increase when plasminogen activators were adminis-
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alfimeprase-treated patients and none of the seven IT
placebo-treated patients who received a plasminogen acti-
vator after drug administration subsequently experienced a
hemorrhagic event.
The hypotensive events associated with alfimeprase
were transient, generally occurring within about 15 min-
utes of drug administration and resolving by 30 minutes
postdose. The use of angiotensin-converting enzyme
(ACE) inhibitors at baseline appeared to increase the risk of
hypotension with alfimeprase. An ACE inhibitor was used
at baseline by 58% of alfimeprase recipients with protocol-
defined hypotension compared to 33% without hypoten-
sion. This observation is consistent with the hypothesis that
the mechanism of alfimeprase-induced hypotension may be
related to the local generation of bradykinin products. The
transient hypotension, including the most severe instances,
did not appear to result in adverse consequences. Other
antihypertensive medications did not show a relationship to
the development of protocol-defined hypotension.
Regardless of the source of peripheral embolism, such
events elevated the risk of subsequent amputation. An
amputation was reported for 27% of patients with an em-
bolism and 12% without an embolism in the alfimeprase
group, and 20% with an embolism and 9% without an
Table VII. Incidence of key adverse events and serious ad
HA004
Alfimeprase IT placebo PT p
(N  148) (N  111) (N 
Any AE 119 (80.4%) 74 (66.7%) 27 (7
P  .0179
Any SAE 55 (37.2%) 32 (28.8%) 10 (2
P  .203
Major hemorrhage 8 (5.4%) 1 (0.9%) 2 (5
P  .107
Stroke/intracranial
hemorrhage 1 (0.7%) 0
P  .889
Hypotensiona as AE 29 (19.6%) 4 (3.6%)
P  .002
Hypotensiona as SAE 4 (2.7%) 0
P  .217
Peripheral embolism 15 (10.1%) 5 (4.5%)
P  .148
Cardiac disorder as AE 24 (16.2%) 2 (1.8%) 5 (1
P  .002
Cardiac disorder as SAE 10 (6.8%) 0 2 (5
P  .0135
Infections as AE 26 (17.6%) 9 (8.1%) 3 (7
P  .043
Infections as SAE 19 (12.8%) 4 (3.6%) 2 (5
P  .018
Major amputation 20 (13.5%) 11 (9.9%) 2 (5
P  .49
Death 9 (6.1%) 4 (3.6%) 1 (2
P  .537
AE, Adverse event; IT, intrathrombus; PT, perithrombus; SAE, serious adv
The P value compared alfimeprase with IT placebo using Pearson’s two-tai
aDefined as “hypotension” or “decreased blood pressure.”embolism in the IT placebo group.Extensive ad hoc analyses concerning the higher fre-
quency of infection events (17.6%), cardiac events (16.2%),
and higher mortality rate (6.1%) were performed. How-
ever, the potential causes for these events among alfime-
prase recipients could not be determined. The types of
infections were varied and there was no imbalance in base-
line medical conditions that may have contributed to infec-
tions or in duration of PAO symptoms. The difference in
cardiac event frequency seen inHA004 was not observed in
HA007 cohorts. In addition, cardiac event frequency dif-
ference could not be explained by an imbalance in baseline
cardiac risk factors, or the incidence of alfimeprase-related
hypotension. The higher rate of cardiovascular events in the
alfimeprase group was reflected in the mortality rate with
cardiovascular causes of death more frequent in the alfime-
prase group. The mortality rate following open vascular
surgery was greater than in patients who avoided such
surgery; however, this finding was consistent across the
alfimeprase and IT placebo groups.
HA007. Adverse events were reported for 73% of
patients in the alfimeprase group and 66% in the placebo
group (Table VII). One placebo-treated patient died due
to sepsis, which was not considered related to study drug.
SAEs were reported for 24% and 28% of patients in the
events (safety population)
HA007 Combined
Alfimeprase IT placebo Alfimeprase Placebo
(N  51) (N  50) (N  199) (N  199)
) 37 (72.5%) 33 (66.0%) 156 (78.4%) 134 (67.3%)
P  .618 P  .018
) 12 (23.5%) 14 (28.0%) 67 (33.7%) 56 (28.1%)
P  .775 P  .277
2 (3.9%) 3 (6.0%) 10 (5.0%) 6 (3.0%)
P  .982 P  .443
0 0 1 (0.50%) 0
P  .996
9 (17.6%) 1 (2.0%) 38 (19.1%) 5 (2.5%)
P  .0214 P  .002
0 0 4 (2.0%) 0
P  .132
5 (9.8%) 0 20 (10.0%) 5 (2.5%)
P  .07 P  .0038
) 3 (5.9%) 3 (6.0%) 27 (13.6%) 10 (5.0%)
P  .69 P  .005
0 1 (2.0%) 10 (5.0%) 3 (1.5%)
P  .99 P  .091
4 (7.8%) 10 (20.0%) 30 (15.1%) 22 (11.1%)
P  .139 P  .298
2 (3.9%) 3 (6.0%) 21 (10.6%) 9 (4.5%)
P  .982 P  .037
3 (5.9%) 6 (12.0%) 23 (11.5%) 19 (9.6%)
P  .465 P  .625
0 1 (2.0%) 9 (4.5%) 6 (3.0%)
P  .99 P  .602
ent.verse
lacebo
38)
1.1%
6.3%
.3%)
0
0
0
0
3.2%
.3%)
.9%)
.3%)
.3%)
.6%)
erse ev
led 2.alfimeprase and IT placebo groups, respectively; only one
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alfimeprase-treated patient).
No patient experienced stroke or intracranial hemor-
rhage. Hemorrhagic events were reported for 9% and 10%
of patients in the alfimeprase and IT placebo groups, re-
spectively, peripheral embolic events for 10% and 0%, and
amputations for 6% and 12%.
Two patients in HA004 and no patients in HA007
terminated before day 30 follow-up due to AEs. The two
patients were both in the IT placebo group, and the AEs
were arterial thrombosis in a limb and a catheter-related
complication. Four patients in the alfimeprase group in
HA004 and two patients in the alfimeprase group and one
patient in the IT placebo group in HA007 did not receive
the second infusion of study drug due to AEs.
Except for hypotension, which was reported more fre-
quently in the alfimeprase group than in the placebo
group(s) in both studies, there were no notable changes in
clinical laboratory tests or vital signs in any treatment
group. Positive results for anti-alfimeprase antibodies at day
30 were found for five patients (two alfimeprase, two IT
placebo, and one PT placebo) in HA004 and no patients in
HA007.
DISCUSSION
The first study of alfimeprase in human subjects was a
multicenter, open-label, single-dose study in 20 patients
with worsening symptoms of lower extremity ischemia
within 6 months of enrollment. Patients were treated with
alfimeprase in five escalating dose cohorts (0.025-0.5 mg/
kg) by intra-arterial and sometimes intrathrombic pulsed
infusion.8 All doses were generally well tolerated and no
bleeding complications were noted.
The next study of alfimeprase was a multicenter, open-
label, phase 2 trial in which 113 patients with acute PAO
received alfimeprase administered in two divided doses
(HA002). The 30-day open vascular surgery avoidance
rates were 69%, 61%, and 52% for patients who received
0.1, 0.3, or 0.6 mg/kg, respectively.9 The overall safety
profile was consistent with a locally acting agent.
Both of the current trials, HA004 and HA007 com-
pared alfimeprase with IT placebo group. In addition, the
HA004 incorporated the perithrombus placebo arm based
on the FDA recommendation. Subsequently, to focus spe-
cifically on the intrathrombus placebo, HA007 did not
include the PT placebo arm and enrolled patients with
slightly more inclusive criteria. The modifications in inclu-
sion criteria for HA007 were agreed upon by the FDA and
the sponsor to be minor and not affecting the validity of the
study. Open vascular surgery avoidance was chosen as the
primary outcome, based on the results of the two largest
thrombolytic trials on acute limb ischemia. The TOPAS
trial showed reduction in the need for open surgical proce-
dures for urokinase, while subgroup analysis of patients
with native artery occlusion from the STILE population
showed initial reduction of surgical procedures for the
thrombolysis group.3,11 Overall in the two controlled stud-
ies, catheter-directed alfimeprase therapy in patients withacute PAO did not result in improvement in the 30-day
open surgery avoidance rate compared to placebo. How-
ever, in HA007, the alfimeprase group showed a trend
toward a higher 30-day open surgery avoidance rate than
the IT placebo group. HA007 also showed a similar pattern
of numerically higher, but not statistically significant, rates
of improvement in arterial flow restoration at 4 hours and
30-day ABI with alfimeprase compared to IT placebo.
HA004 showed equivalent secondary outcomes between
alfimeprase and IT placebo, namely arterial flow restoration
at 4 hours, 30-day ABI, index limb pain severity, and
severity of planned surgical procedure.
The results support at least a certain thrombolytic effect
of alfimeprase, although smaller than expected. In particu-
lar, the observations in HA004 of a greater effect with
increased clot size and with smaller decreases in 2M,
which binds rapidly and irreversibly to alfimeprase, suggest
that the findings may be related to the delivery method and
how long alfimeprase is present in the clot. When 2M did
not show an early decline, indicating retention of alfime-
prase within the thrombus, the 4-hour flow restoration rate
was 70% with alfimeprase compared with 37% with IT
placebo (Table VI).
Our primary outcome results with alfimeprase are con-
trary to the previous reports regarding conventional throm-
bolytic agents and the HA002 phase 2 trial for alfimeprase.
For example, a 55.8% reduction of severity of surgery was
seen with thrombolysis in the STILE trial, while the
TOPAS trial showed a 43% reduction in the need for open
surgery at 6 months. The failure of our studies to show a
difference in primary outcomes may be a reflection of
inadequate dosing and/or mode of delivery of alfimeprase.
Rates of arterial flow restoration achieved in our studies
were 35.3% to 46.3% in alfimeprase groups, which were
much lower than the 79.7% recanalization and 67.9% com-
plete dissolution rates reported in the TOPAS trial, as well
as the 70% dissolution rate in the Rochester trial.3,10 It is
possible that the 0.3 mg/kg dosing of alfimeprase was
insufficient to result in clot dissolution in enough patients
to have a statistically and clinically significant impact on the
primary outcome. Inadequate dosing might explain the
similarity in outcomes between alfimeprase and IT placebo,
but worse outcomes with PT placebo. In other words,
arterial flow restoration achieved with alfimeprase may have
been due tomechanical effects of intrathrombus pulse spray
rather than fibrinolysis.
One explanation for the discrepancy in clot dissolution
rates seen in our studies compared with the previous
thrombolysis trials is the possibility of more extensive un-
derlying atherosclerotic disease in our study population.
However, the patient characteristics in this study were
similar to those from previous trials in age, sex, duration of
symptoms, and concurrent medical illnesses. Albeit the
difficulty of delineating true thrombosis from embolism in
acute limb ischemia, the length of the occluding lesion in
our study was less with median clot sizes of 15 to 20 cm,
compared with 32 cm reported in the TOPAS trial. This
lower thrombus burden might have resulted in decreased
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decrease in fibrolytic activity. Additionally, the smaller
thrombus burden appears to have contributed to the suc-
cessful recanalization in the placebo group, which was
observed in 55% of the IT placebo group with occlusion
length 10 cm.
An interesting similarity between the current studies
and the STILE trial is the lack of benefit observed when
treating native arterial occlusions. While the STILE trial
showed significant benefit of catheter-directed thromboly-
sis in patients with acute limb ischemia (2 weeks), the
benefit was the result of success enjoyed by patients with
acute graft occlusion,2 not native artery occlusion.11 In
HA004, 33% of patients were treated for graft occlusion.
These patients had a numerically more favorable outcome
with intrathrombus delivery of alfimeprase than placebo
alone, while there was no difference in efficacy for native
vessel occlusion. This disparity seen in native and graft
occlusion may be explained by quicker metabolism by 2M
present in native vessel, but not in graft.
The equivalent outcomes between IT placebo and
alfimeprase groups, namely the 30-day surgery avoidance
rate, flow restoration, and 30-day limb pain improvement,
deserve comment. As mentioned above, the similar flow
restoration by alfimeprase and IT placebo groups may be a
reflection of ineffectual lytic actions by alfimeprase or poor
localization of the drug due to the low local thrombus
burden at the delivery site. Furthermore, the fact that IT
placebo and not PT placebo was able to achieve similar
outcomes to alfimeprase indicates that the rheolytic effect
of the saline spray may be important. In any event, the
effectiveness of the IT placebo is consistent with the addi-
tive benefit of mechanical therapy for acute limb ischemia.
Our findings are unique in that none of the previous
landmark thrombolytic trials have incorporated placebo
groups. To date, study HA004 is the first one to evaluate
placebo effects in two different modes (intrathrombus and
perithrombus) of delivery. These results indicate that sub-
sequent lytic trials should incorporate a placebo arm to
account for possible rheolytic effects of catheter delivery.
Surprisingly, rates of 30-day open vascular surgery
avoidance for alfimeprase were approximately half of the
61% found in study HA002. Since the projected success
rate of 61% was used in our sample calculation, the much
lower observed success rate of alfimeprase may have sub-
stantially increased the risk of a type II error in our primary
outcome findings. Furthermore, a large proportion of pa-
tients who failed alfimeprase therapy may have masked a
possible difference in primary outcomes in both HA004
andHA007 trials, contributing to the risk of a type II error.
We were surprised to see different safety data from the
HA004 and HA007 trials. HA004 revealed more overall
AEs in the alfimeprase group compared to IT and PT
placebo groups. Of these AEs, hemorrhagic and peripheral
embolic events were higher with the alfimeprase group at
23% and 10.1%, respectively. In HA007, hemorrhagic
event rate was 9.4% and peripheral embolic event rate was
9.8%. The development of peripheral embolism appearedto be a consequence of both the mechanical disruption of
the thrombus by placement of the catheter within the
thrombus and pulsed spray injection of study drug as well as
by the thrombolytic effect of alfimeprase. There were no
life-threatening or intracranial hemorrhages in either trial.
No deaths were related to the study medications. This is
consistent with the previous phase 1 and phase 2 alfime-
prase trials, which also showed no serious bleeding events
attributable to alfimeprase.8 Despite the extensive ad hoc
analyses, etiologies for the higher frequency of infection,
and cardiac events in alfimeprase group could not be deter-
mined. The types of infections were varied, and there was
no baseline medical condition that may have contributed to
infections or in duration of PAO symptoms. Cardiac event
frequency could not be explained by baseline cardiac risk
factors or the incidence of alfimeprase-related hypotension.
The reported bleeding complication rates were 15% to 36%
in the Rochester trial and 12.5% in the TOPAS trial, which
were similar to those seen in our study. However, compar-
ison between hemorrhagic complications of alfimeprase
and conventional thrombolytic agents in acute limb isch-
emia would only be appropriate in a prospective random-
ized controlled trial of alfimeprase versus plasminogen ac-
tivators. Statistically, it is difficult to draw much inference
from the safety data, since the study was mainly designed to
test our hypothesis on the primary outcome.
In summary, catheter-directed alfimeprase therapy did
not have a statistically significant impact on 30-day freedom
from open vascular surgery compared with placebo. Alfime-
prase appears to be safe with low overall rates of SAEs and,
most importantly, no life-threatening bleeding complica-
tions. Further studies are warranted to determine the opti-
mal dosing and delivery method of alfimeprase in acute
arterial occlusion. Other clinical outcome measures such as
amputation-free and overall survival rates should be evalu-
ated in the future. Our study findings suggest that a placebo
control should be considered in designing future thrombo-
lytic trials. Furthermore, the critical nature of the drug
delivery mode is illustrated in this study. Traditional modes
of drug delivery may not be adequate for drugs that are only
active within thrombus. Finally, prospective randomized
trials comparing alfimeprase to the conventional thrombo-
lytic agents would be helpful in further elucidating poten-
tial advantages of alfimeprase.
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1998;28:1072-81.INVITED COMMENTARYVikram S. Kashyap, MD, Cleveland, Ohio
The publication of a randomized controlled trial in the vascular
arena is rare. The publication of a trial with negative results is rarer.
Han and colleagues should be applauded for an honest portrayal of
the use of alfimeprase in the setting of acute limb ischemia (ALI).
Alfimeprase, a novel recombinant variant of fibrolase, displayed prom-
ising results in preclinical and pilot studies. In contrast to available
thrombolytic agents, alfimeprase is a direct fibrinolytic enzyme and
has no effect on plasminogen. In addition, any drug that escapes into
the general circulation is quickly degraded by 2-macroglobulin
which is ubiquitous in plasma. These properties have the potential to
overcome limitations that exist with current therapies: the duration of
therapy and the risk of bleeding. A rapidly-acting, direct fibrinolytic
without systemic plasminogen activation and plasma neutralization
seem like ideal characteristics for a thrombolytic agent. In this report,
data from two essentially blinded, placebo-controlled, randomized
controlled trials evaluating alfimeprase for ALI are reported. Alas,
alfimeprase showed no greater effectiveness than placebo in ALI
patients withmostly femoral/popliteal thrombus in native arteries. In
fact, the rates of distal embolization and amputation in the treatment
groups were troubling.
Trial design is a critical component in the analyses of anyopen vascular surgery at 30 days” may not be a realistic endpoint in
patients with ALI. Thrombolysis may be the only therapy required
for patients with an embolus in an otherwise normal arterial tree.
However, most patients reported in these trials developed ALI
from thrombosis in the setting of extensive atherosclerotic occlu-
sive disease. The dissolution of thrombus uncovers a culprit lesion
which may require a limited surgical procedure for durable pa-
tency. Time to patency, cost, resource utilization, and grading of
the extent of open surgery are surrogate endpoints that can be used
for ALI trials and would likely favor alfimeprase in future studies.
Amputation-free survival is perhaps the best global endpoint, but
one that requires a large sample size. The inclusion of a placebo
group is difficult since acceptable results are obtained with throm-
bolysis in patients that are often ill-prepared to withstand major
limb revascularization. In fact, the surprising “effectiveness” of
intrathrombus placebo leads to the alternative conclusion that
percutaneousmechanical thrombectomy devices utilizing rheolysis
may be clinically beneficial in most cases of ALI. The compelling
preclinical data on alfimeprase did not translate into clinical effi-
cacy. Enhanced dosing and delivery strategies may salvage alfime-
prase. I agree with the authors that further study is warranted.
